Cellular Origins Advances Automation For Scalable Cell Therapy Manufacturing In Collaboration With Immatics

Cellular Origins to collaborate with Immatics on automation for cell therapy manufacturing

Cellular Origins, enabling the manufacturing of cell therapies at scale, today announced a collaboration with Immatics a late-stage clinical biopharmaceutical company and the global leader in precision targeting of PRAME for the production of Immatics’ immuno-oncology cell therapies.

Under the agreement, the Parties are working to utilise Cellular Origin’s automated mobile robotic platform, Constellation, within certain parts of the company’s manufacturing processes. The collaboration will explore how automation technologies can further contribute to more efficient and scalable manufacturing processes for next-generation cell therapies.

Automation is increasingly recognised as an important enhancer for the broader adoption of cell therapies by helping optimise manufacturing consistency, scalability, and operational efficiency. Under the collaboration, Immatics is working with Cellular Origins on the Constellation platform for the automation of selected manufacturing operations. Cellular Origins’ experience and progress in integrating technologies from leading CGT equipment suppliers was an important factor in the decision. The programme is planned to be delivered in a series of defined phases and milestones, with the initial phase expected for completion in 2026.

“Following the first cell therapy approvals in 2017, there has been widespread success in treating blood cancers, while progress in solid tumours has been more limited. Immatics is now working to advance clinically validated approaches that could expand treatment options for these,” said Edwin Stone, CEO, Cellular Origins. “Current manual manufacturing methods can limit the number of patients who are able to access approved therapies. Effective cell therapies for solid-tumour patients is one of the most exciting developments in our field but will need the manufacturing challenges to be addressed to deliver on its potential. Our partnership with Immatics aims to support the scalable and cost-effective manufacturing of their therapies so that more patients could potentially benefit.”

“Immatics has generated extensive data demonstrating the potential of precision targeting PRAME, a target expressed in more than 50 cancers,” said Ali Mohamed, SVP, of CMC, Immatics. “As we continue to advance our programs, it is important that we also develop manufacturing capabilities that can support future scale. We are pleased to collaborate with Cellular Origins to explore how the Constellation platform and our integrated manufacturing processes could support the scalable production of our therapies as we move toward potential approvals.”

About Cellular Origins
Cellular Origins is enabling the manufacture of cell therapies at scale through a flexible, factory-led automation platform that adapts to existing processes and facilities. Its Constellation ecosystem unites mobile robotics, and automated sterile welding with proven bioprocess instruments, eliminating the need for therapy redevelopment and providing a dependable route from clinical to commercial manufacture. Designed to flex around any facility and to evolve with advancing therapies, the Constellation platform provides a flexible, future-proof foundation for large scale production and wider ATMP growth. Trusted by market leaders including Cytiva, Fresenius Kabi, Thermo Fisher Scientific and Wilson Wolf, Cellular Origins is building the automation infrastructure required to scale manufacture of 100,000s of doses of transformative therapies reliably and efficiently. For more information, visit www.cellularorigins.com.